Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Texas Southwestern Medical Center | OTHER |
| Van Andel Research Institute | OTHER |
| University of Victoria | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. This observational study involves intravenous infusion of [U-13C]glucose into patients during standard paracentesis.
Participants and Location:
This study will recruit up to 10 patients of at least 18 years of age with ascites due to diagnosed ovarian cancer. Eligible study patients will be screened and recruited at BC Cancer - Victoria. Paracentesis procedure and patient consent will occur at the Island Health - Royal Jubilee Hospital.
Study Design:
Participants meeting the inclusion criteria will be fitted with a continuous glucose monitor (FreeStyle Libre) before proceeding to their scheduled appointment for paracentesis. Labeled glucose will be administered via I.V. at dose of 8g of labeled glucose in 60 mL over 10 min. This is followed by 4g of labeled glucose in 30 mL over an hour.
Sample collection and processing:
During [U-13C]glucose infusions, the ascites specimens will kept on ice. Samples will be collected and analyzed by flow cytometry and mass spectrometry for states of metabolism and metabolite profiles respectively. The ascites fluid will be monitored for changes in metabolite levels.
[U-13C]glucose Product Information:
[U-13C]glucose clinical grade will be compound BC Cancer Pharmacy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| [U-13C]glucose | All participants consented to the study will receive the [U-13C]glucose infusion and collection of ascites for research. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| [U-13C]Glucose | Dietary Supplement | Patients are intravenously infused with 28g of [U-13C]glucose over a 5 hour period. Briefly, [U-13C]glucose will be provided by intravenous line containing 8g of [U-13C]glucose in 60 mL over 10 min. After 10 minutes, 4g of [U-13C]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor. |
| Measure | Description | Time Frame |
|---|---|---|
| Achieve [U-13C]Glucose enrichment in the ascites of ovarian cancer patients | Extracellular [U-13C]Glucose label enrichment in the ascites fluid (measured by mass spectrometry). | Duration of ascites paracentesis (samples collected hourly, up to 5 hours) |
| Compare glucose uptake and metabolic pathways in different cell populations in the ascites. | Fractional enrichment of intracellular [U-13C]Glucose and 13C labeled metabolites in T cells, myeloid cells and tumour cells (measured by mass spectrometry). | Duration of ascites paracentesis (samples collected hourly, up to 5 hours) |
| Measure | Description | Time Frame |
|---|---|---|
| Correlate metabolic profiles with functionality of T cells found in the ascites. | Multi-parametric flow cytometry analysis of glucose uptake, mitochondrial function, T cell phenotypes and function. | One time - Duration of ascites paracentesis |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adults over the age of 18 with ascites due to diagnosed ovarian cancer.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julian J. Lum, PhD | Contact | 250-519-5700 | JLum@bccancer.bc.ca | |
| Jennifer Rauw, MD | Contact | 250-519-5500 | Jennifer.Rauw@bccancer.bc.ca |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Jennifer Rauw | Recruiting | Victoria | British Columbia | Canada |
Not provided
| ID | Term |
|---|---|
| D010051 | Ovarian Neoplasms |
| D001201 | Ascites |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| D000291 |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |